Trial Profile
Phase I trial of STI 6991 for COVID-2019 infection (Prevention) in USA
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 01 Apr 2020
At a glance
- Drugs STI 6991 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
- 01 Apr 2020 New trial record
- 25 Mar 2020 According to Sorrento Therapeutics media release, the company aims to start enrolling in a human clinical trial as early as mid-year 2020
Most Recent Events
Trial Overview
Purpose
Phase I trial of STI 6991 for COVID-2019 infection (Prevention) in USA in mid-2020 (IM)
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | prevention | - |
Subjects
- Subject Type patients
- Sex not stated
Trial Details
Organisations
- Sponsors Sorrento Therapeutics
- Affiliations Sorrento Therapeutics
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location USA
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| STI 6991Primary Drug | Intramuscular |
-
|
STI 6991
Trial Centres
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 01 Apr 2020 | New trial record | New trial record Updated 01 Apr 2020 |
| 25 Mar 2020 | Other trial event | According to Sorrento Therapeutics media release, the company aims to start enrolling in a human clinical trial as early as mid-year 2020 Updated 01 Apr 2020 |
References
-
Sorrento Therapeutics. Sorrento Launches Novel I-Cell(TM) COVID-19 Cellular Vaccine Program. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG